{"gene":"IKZF3","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2013,"finding":"Lenalidomide causes selective ubiquitination and degradation of IKZF3 (Aiolos) by the CRBN-CRL4 E3 ubiquitin ligase complex; a single amino acid substitution in IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth. IKZF3 degradation also mediates lenalidomide-induced IL-2 production in T cells.","method":"Quantitative proteomics, ubiquitination assays, mutagenesis (single amino acid substitution), cell growth rescue experiments","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 / Strong — quantitative proteomics combined with mutagenesis and functional rescue, replicated across multiple studies","pmids":["24292625"],"is_preprint":false},{"year":2013,"finding":"Lenalidomide and pomalidomide induce interaction of IKZF3 (Aiolos) with CRL4(CRBN), promoting IKZF3 binding to the complex, enhanced ubiquitination, and cereblon-dependent proteasomal degradation in T lymphocytes. IKZF3 and IKZF1 function as transcriptional repressors of IL-2 expression.","method":"Co-immunoprecipitation, ubiquitination assays, Western blot, flow cytometry, reporter gene assays","journal":"British journal of haematology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, multiple orthogonal methods, independently replicates PMID 24292625","pmids":["24328678"],"is_preprint":false},{"year":1997,"finding":"IKZF3 (Aiolos) heterodimerizes with Ikaros proteins; mutant dominant-negative Ikaros isoforms interfere with Aiolos activity, demonstrating functional interdependence. Aiolos homo- and heteromeric complexes with Ikaros have distinct relative transcriptional activities.","method":"Molecular cloning, protein interaction studies (heterodimerization assays), transcriptional activity assays, expression analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct heterodimerization demonstrated biochemically with functional validation, foundational study replicated widely","pmids":["9155026"],"is_preprint":false},{"year":1998,"finding":"Aiolos-null B cells exhibit augmented BCR-mediated proliferative responses and an activated surface phenotype, establishing Aiolos as a negative regulator of BCR signaling and B cell activation. Peritoneal, marginal zone, and recirculating bone marrow B cell populations are greatly reduced in Aiolos-deficient mice.","method":"Aiolos-null mouse model, in vitro BCR stimulation proliferation assays, flow cytometry, in vivo immunization","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic null model with defined cellular phenotype, multiple orthogonal readouts","pmids":["9806640"],"is_preprint":false},{"year":1999,"finding":"Ikaros and Aiolos function as transcriptional repressors through two repression domains; repression correlates with histone deacetylation at promoters and is relieved by HDAC inhibitors. Ikaros/Aiolos repression domains interact in vivo and in vitro with mSin3 co-repressors that bind HDACs.","method":"Transcriptional repression assays, HDAC inhibitor treatment, histone acetylation assays (chromatin), co-immunoprecipitation (in vivo and in vitro)","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro and in vivo interaction assays combined with functional histone modification readouts, replicated","pmids":["10357820"],"is_preprint":false},{"year":1999,"finding":"Aiolos interacts with Ras in T cells; IL-2 controls subcellular distribution of Aiolos and induces its tyrosine phosphorylation, required for dissociation from Ras. Aiolos binds functional sites in the Bcl-2 promoter and activates Bcl-2 transcription, preventing apoptosis in IL-2-deprived cells.","method":"Co-immunoprecipitation (in vitro and in vivo), indirect immunofluorescence, promoter reporter (luciferase) assays, site-directed mutagenesis of Bcl-2 promoter, co-transfection experiments","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple methods in one study including Co-IP, mutagenesis, and functional reporter assays, single lab","pmids":["10369681"],"is_preprint":false},{"year":2001,"finding":"Aiolos associates with Bcl-xL in IL-4-stimulated T cells; IL-4 deprivation increases the Bcl-xL/Aiolos interaction. IL-4 induces tyrosine phosphorylation of Aiolos, required for dissociation from Bcl-xL. Cells overexpressing both Bcl-xL and Aiolos cannot block apoptosis, establishing Aiolos as a regulator of Bcl-xL anti-apoptotic function.","method":"Yeast two-hybrid, co-immunoprecipitation, indirect immunofluorescence, co-transfection overexpression experiments","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — yeast two-hybrid validated by Co-IP and functional assays, single lab","pmids":["11714801"],"is_preprint":false},{"year":2001,"finding":"BCR signaling and MZ B cell development are regulated by Aiolos in epistasis with Btk and CD21; loss of Aiolos enhances follicular B cell maturation signals through a pathway requiring Btk, placing Btk downstream of (epistatic to) Aiolos.","method":"Genetic epistasis analysis using Aiolos-null, Btk-null, and CD21-null mouse models","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with multiple null mouse models, single study","pmids":["11371362"],"is_preprint":false},{"year":2004,"finding":"Aiolos is specifically required (in a B cell-intrinsic manner demonstrated by chimera reconstitution) for the generation of high-affinity bone marrow plasma cells responsible for long-term immunity, without affecting somatic hypermutation, memory B cells, or short-lived splenic plasma cells.","method":"Aiolos-null mouse model, bone marrow chimera reconstitution, serum antibody titer measurement, immunization with hapten concentrations","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — chimera reconstitution establishes B cell-intrinsic requirement, multiple orthogonal readouts","pmids":["14718515"],"is_preprint":false},{"year":2010,"finding":"Aiolos and Ikaros directly bind the c-Myc promoter in pre-B cells in vivo and suppress c-Myc expression. Downregulation of c-Myc is required for the growth-inhibitory effect of Aiolos/Ikaros and precedes p27 induction and cyclin D3 downregulation, establishing c-Myc as a direct downstream target.","method":"ChIP (chromatin immunoprecipitation), gene expression analysis, gain/loss-of-function in pre-B cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter binding plus functional epistasis experiments, single lab with multiple methods","pmids":["20566697"],"is_preprint":false},{"year":2007,"finding":"IRF4 and IRF8 induce Aiolos expression in pre-B cells; reconstitution of Aiolos (or Ikaros) expression is sufficient to suppress surrogate light chain expression and down-regulate pre-BCR in cells lacking IRF4/8. Aiolos is required downstream of IRF4/8 for cell-cycle withdrawal.","method":"Gain- and loss-of-function experiments in pre-B cells, gene expression analysis, cell cycle analysis","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution and loss-of-function experiments establishing pathway position, single lab","pmids":["17971486"],"is_preprint":false},{"year":2012,"finding":"Under TH17-polarizing conditions, STAT3 and AhR upregulate Aiolos expression. Aiolos directly silences the Il2 locus, promoting TH17 differentiation in vitro and in vivo, demonstrated using Aiolos-deficient mice.","method":"Aiolos-deficient mouse model, in vitro and in vivo TH17 differentiation assays, chromatin analysis of Il2 locus","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic null model with in vitro and in vivo validation, upstream regulators identified","pmids":["22751139"],"is_preprint":false},{"year":2014,"finding":"Aiolos is required for peripheral NK cell maturation; Aiolos expression is initiated at NK lineage commitment. Loss of Aiolos causes a block in CD11b(high)CD27(-) NK cell maturation intrinsic to the NK lineage, and genetic analysis revealed Aiolos acts independently of T-bet and Blimp1.","method":"Aiolos-null mouse model, flow cytometry of NK maturation stages, cell surface marker analysis, genetic epistasis with T-bet and Blimp1 null mice, NK cell tumor and viral infection models","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic null plus epistasis with multiple other TF knockouts, intrinsic defect demonstrated","pmids":["25319415"],"is_preprint":false},{"year":2014,"finding":"Aiolos reconfigures chromatin structure within the SHC1 gene, causing isoform-specific silencing of p66Shc (an anchorage reporter), blocking anoikis. Aiolos also decreases expression of adhesion-related genes, disrupting cell-cell and cell-matrix interactions in cancer cells.","method":"Chromatin analysis (epigenetic assays), gene expression profiling, anoikis assays in vitro and in vivo (xenograft)","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromatin remodeling and functional anoikis assays, single lab, multiple methods","pmids":["24823637"],"is_preprint":false},{"year":2015,"finding":"The rate (half-maximal rate) of CRL4(CRBN)-dependent Aiolos and Ikaros degradation—not the final extent—correlates with the relative anti-proliferative efficacy of lenalidomide vs. pomalidomide. Sequential downregulation of Aiolos/Ikaros → c-Myc → IRF4 is required for growth inhibition and apoptosis in MM cells.","method":"Kinetic degradation analysis, Western blot time course, cell growth inhibition and apoptosis assays","journal":"Blood cancer journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinetic analysis with multiple cell lines, single lab","pmids":["26430725"],"is_preprint":false},{"year":2016,"finding":"Aiolos interacts with Blimp-1 in multiple myeloma cells (identified by mass spectrometry). Aiolos and Blimp-1 co-bind a large number of genomic targets including apoptosis-related genes. Aiolos promotes Blimp-1 binding to target genes and enhances Blimp-1-dependent transcriptional repression.","method":"Mass spectrometry (Aiolos-Blimp-1 interaction), ChIP-chip (genome-wide co-binding), transcriptome analysis, functional repression assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MS-identified interaction validated by ChIP with functional transcriptional readout, single lab","pmids":["26823144"],"is_preprint":false},{"year":2017,"finding":"CC-220 (iberdomide) binds cereblon with higher affinity than lenalidomide or pomalidomide, resulting in more potent and extensive cellular degradation of Ikaros and Aiolos. Crystal structure of cereblon-DDB1-CC-220 complex reveals additional contacts between CC-220 and cereblon outside the modeled IKZF1/IKZF3 binding site that account for increased potency.","method":"Crystal structure (X-ray crystallography) of cereblon-DDB1-compound complex, binding affinity measurements, cellular degradation assays","journal":"Journal of medicinal chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with functional degradation assays demonstrating structure-function relationship","pmids":["28425720"],"is_preprint":false},{"year":2018,"finding":"CRISPR-Cas9 deletion of IKZF3 (Aiolos) alone in MM cell lines recapitulates IMiD-induced cell cycle arrest and apoptosis. Aiolos/Ikaros repress interferon-stimulated genes (ISGs) including CD38 through interaction with the NuRD (nucleosome remodeling and deacetylase) complex, and their loss activates an interferon-like response that contributes to MM cell death and increases CD38 surface expression.","method":"CRISPR-Cas9 knockout, RNA-seq transcriptomics, co-immunoprecipitation (NuRD complex association), flow cytometry (CD38 surface expression), NK cell ADCC assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR knockout with multiple orthogonal functional readouts and Co-IP for NuRD interaction, single lab","pmids":["30228232"],"is_preprint":false},{"year":2021,"finding":"A heterozygous IKZF3 missense variant (G→R in DNA-binding domain) causes mutant AIOLOS homodimers and AIOLOS-IKAROS heterodimers to fail binding the canonical DNA sequence. Instead, these dimers bind genomic regions lacking canonical motifs. Removal of the dimerization capacity from mutant AIOLOS restored B cell development, establishing that the dominance is due to heterodimeric interference with IKAROS function.","method":"Mouse knockin model (corresponding variant), DNA binding assays, ChIP-seq (altered genomic targeting), B cell development analysis, dimerization-deficient variant rescue experiments","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockin mouse model with DNA binding, ChIP-seq, and dimerization-deficient rescue experiments, multiple orthogonal methods","pmids":["34155405"],"is_preprint":false},{"year":2021,"finding":"The IKZF3-L162R hotspot mutation alters DNA binding specificity and target gene selection, causing hyperactivation of BCR signaling and overexpression of NF-κB target genes, driving CLL-like disease in a conditional knockin mouse model (~40% penetrance).","method":"B cell-restricted conditional knockin mouse model, ChIP-seq (altered DNA binding), RNA-seq, BCR signaling assays (ibrutinib sensitivity)","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional knockin mouse model with ChIP-seq and signaling pathway validation, multiple orthogonal methods","pmids":["33689703"],"is_preprint":false},{"year":2021,"finding":"AIOLOS p.N160S heterozygous variant causes dominant-negative impairment of B and T cell development; mutant protein fails DNA binding and pericentromeric targeting. The mutant has a dominant-negative effect over WT AIOLOS but not WT IKAROS.","method":"Patient analysis, in vitro DNA binding assays, pericentromeric targeting assays, murine model recapitulation","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro binding and localization assays with mouse model validation, single study","pmids":["34694366"],"is_preprint":false},{"year":2007,"finding":"Full-length Aiolos isoforms localize to heterochromatin; different Aiolos isoforms arising from alternative splicing have distinct abilities to heterodimerize with Ikaros, associate with HDAC-containing complexes, and produce histone modifications. The cellular activities of Aiolos are dependent on combinations of functional domains determined by differential splicing.","method":"Cellular localization studies (immunofluorescence), co-immunoprecipitation (Ikaros heterodimerization, HDAC complex), histone modification assays, DNA-binding assays of isoforms","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple methods in single study examining isoform-specific functions, single lab","pmids":["17646674"],"is_preprint":false},{"year":2008,"finding":"Aiolos and OBF-1 cooperate to silence lambda5 surrogate light chain gene expression and mediate its developmentally regulated nuclear repositioning at the pre-B cell stage; without both factors, lambda5 and VpreB fail to be efficiently silenced, and nuclear repositioning of lambda5 is impaired.","method":"Aiolos/OBF-1 double-knockout mouse model, gene expression analysis, nuclear repositioning assays (FISH), light chain rearrangement analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic model with nuclear localization readout and functional gene silencing validation, single lab","pmids":["18974788"],"is_preprint":false},{"year":2003,"finding":"OBF-1 is required for the SLE-like phenotypes in Aiolos-null mice; loss of OBF-1 reverses B cell hyperproliferation, activation marker overexpression, and spontaneous germinal center formation in Aiolos-null mice. The double-mutant mice show a block in pre-B to immature B cell transition, establishing that Aiolos suppresses OBF-1-dependent B cell activation.","method":"Aiolos/OBF-1 double-knockout mouse model, flow cytometry, B cell proliferation assays, antibody measurements","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with double-knockout model, multiple cellular phenotype readouts, single lab","pmids":["12574333"],"is_preprint":false},{"year":2019,"finding":"N160 is a key amino acid for IKZF3 DNA-binding activity; mutation of N160A results in loss of peripheral heterochromatin localization, dissociation from target genes, and inability to change target gene expression.","method":"Site-directed mutagenesis (N160A), immunofluorescence (heterochromatin localization), ChIP (target gene association), gene expression analysis","journal":"Anatomical record (Hoboken, N.J. : 2007)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis with multiple functional readouts (localization, ChIP, expression), single lab","pmids":["31251838"],"is_preprint":false},{"year":2023,"finding":"Aiolos deficiency results in reduced expression of key TFH transcription factors and reduced TFH differentiation during influenza infection, while CD4-CTL programming is elevated with enhanced Eomes and cytolytic molecule expression. Aiolos deficiency allows enhanced IL-2 sensitivity and increased STAT5 association with CD4-CTL gene targets including Eomes, effector molecules, and IL2Ra.","method":"Aiolos-deficient mouse model (influenza infection), flow cytometry, ChIP (STAT5 occupancy at CD4-CTL gene targets), gene expression analysis","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null model with in vivo infection and ChIP for direct mechanism, single lab","pmids":["36964178"],"is_preprint":false},{"year":2024,"finding":"IKZF1 (Ikaros) and IKZF3 (Aiolos) directly bind AP-1 family transcription factors; deletion of both Ikzf1 and Ikzf3 in NK cells results in further reduction of Jun/Fos expression and complete loss of peripheral NK cells. IKZF3 upregulation is observed in Ikzf1-null NK cells, indicating compensatory regulation.","method":"Conditional genetic inactivation in NK cells (Ikzf1 and Ikzf3 single and double conditional KO), ChIP (direct AP-1 binding), transcriptional analysis, flow cytometry","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional double KO with ChIP-demonstrated direct binding and functional NK cell phenotype, single lab with multiple orthogonal methods","pmids":["38182668"],"is_preprint":false},{"year":2024,"finding":"AIOLOS zinc finger 5-6 domain is required for dimerization; a Q402* truncation mutant lacking ZF5-6 can still homodimerize with WT AIOLOS and negatively regulates DNA binding through ZF1 (a previously unrecognized function for this domain). An E82K variant leads to haploinsufficiency by affecting a protein stability domain.","method":"Patient variant analysis, in vitro DNA binding assays, pericentromeric targeting assays, transcriptome analysis, protein stability assays, homodimerization assays","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple biochemical assays defining domain function, single study with 3 families","pmids":["38015619"],"is_preprint":false},{"year":2024,"finding":"Aiolos represses Eomes expression and the IL-15R subunit CD122 (CD8+ T cell virtual memory regulators); Aiolos-deficient mice show enhanced virtual memory CD8+ T cell frequency and function, establishing Aiolos as a molecular repressor of virtual memory T cell programming.","method":"Ikzf3-/- mouse model, flow cytometry, cytokine stimulation assays, gene expression analysis, influenza infection model","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null model with mechanistic targets (Eomes, CD122), single lab","pmids":["41392082"],"is_preprint":false},{"year":2024,"finding":"PBK/TOPK mitotic kinase phosphorylates Aiolos (IKZF3) to promote its dissociation from chromosomes during mitosis; Aiolos is retained on mitotic chromosomes in Pbk-/- cells, and PBK inhibitor OTS514 rapidly reverses Aiolos eviction from chromosomes.","method":"Pbk-/- mouse model, mitotic chromosome fractionation proteomics, immunofluorescence, PBK inhibitor (OTS514) treatment, ATAC-seq (chromatin accessibility)","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null plus pharmacological inhibition with proteomics and functional chromatin readouts, single lab","pmids":["40987773"],"is_preprint":false},{"year":2024,"finding":"Aiolos promotes CXCR3 expression on Th1 cells by sustaining expression of JAK2 and STAT1; Aiolos deficiency reduces STAT1 tyrosine phosphorylation and STAT1 enrichment at the Cxcr3 promoter. Aiolos and STAT1 form a positive feedback loop via reciprocal regulation downstream of IFN-γ signaling.","method":"Aiolos-deficient mouse model (influenza infection), ChIP (STAT1 at Cxcr3 promoter), flow cytometry (phospho-STAT1), gene expression analysis","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null model with ChIP for direct promoter occupancy, single lab","pmids":["39560988"],"is_preprint":false},{"year":2024,"finding":"Aiolos is a downstream effector of Kidins220 during thymic iNKT cell development. Aiolos expression is downregulated in Kidins220-deficient iNKT cells, and Aiolos KO phenocopies enhanced apoptosis at iNKT stages 2 and 3, placing Aiolos downstream of Kidins220 in this pathway.","method":"T cell-specific Kidins220 KO mouse model, Aiolos KO mouse model, scRNA-seq, flow cytometry, apoptosis assays","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with two KO models and scRNA-seq, single lab","pmids":["38489359"],"is_preprint":false},{"year":2021,"finding":"Aiolos facilitates eosinophil tissue homing by supporting IL-5 production and ST2+ ILC2 proliferation through inhibiting PD-1. Aiolos deficiency reduces eosinophil CCR3 surface expression, intracellular ERK1/2 signaling, and CCL11-induced actin polymerization, impairing chemotaxis.","method":"Aiolos-deficient mouse model, chimeric mouse model (intrinsic requirement), flow cytometry, ERK1/2 signaling assays, actin polymerization assay, in vivo inflammatory models","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null plus chimeric model establishing intrinsic requirement, multiple signaling assays, single lab","pmids":["34341502"],"is_preprint":false},{"year":2024,"finding":"In vitro acute protein degradation in mice revealed that Aiolos (together with Ikaros) acts as a dedicated transcriptional repressor to cooperatively control early B cell development; both directly repress surrogate light chain genes Igll1 and Vpreb1 in small pre-B cells.","method":"Acute protein degradation (auxin-inducible degron) in mice, ChIP-seq, RNA-seq, chromatin accessibility assays","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — acute protein degradation combined with ChIP-seq directly demonstrating repressor function at specific target loci, rigorous method","pmids":["39179932"],"is_preprint":false},{"year":2023,"finding":"Aiolos restrains intestinal intraepithelial lymphocyte (IEL) activation; Ikzf3-/- CD8αα+ IELs show elevated NK receptors, cytotoxic enzymes, cytokines, and chemokines. Aiolos binding sites are proximal to STAT5 and RUNX binding sites, and Ikzf3 deficiency increases chromatin accessibility and histone acetylation in these regions. Ikzf3 deficiency enhances IL-15 responsiveness of IELs.","method":"Ikzf3-/- mouse model, scRNA-seq, ATAC-seq (chromatin accessibility), histone acetylation assays, IL-15 signaling assays, colitis model","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic null with scRNA-seq, ATAC-seq, and functional signaling assays, multiple orthogonal methods","pmids":["38049581"],"is_preprint":false},{"year":2024,"finding":"Aiolos (IKZF3) represses Eos (IKZF4) expression by antagonizing STAT5-dependent activation of the Ikzf4 promoter; this establishes opposing roles of Aiolos and Eos in regulating CD4-CTL cytotoxic programming.","method":"Aiolos-deficient and Eos-deficient mouse models (influenza infection), ChIP (STAT5 occupancy at Ikzf4 promoter), flow cytometry, gene expression analysis","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic null models with ChIP demonstrating direct promoter regulation, single lab","pmids":["38363226"],"is_preprint":false},{"year":2024,"finding":"OTUB1, a deubiquitinating enzyme, specifically binds Aiolos and reduces its ubiquitination, potentially influencing Aiolos stability and its biological functions in lung cancer cell migration and invasion.","method":"Co-immunoprecipitation (OTUB1-Aiolos interaction), ubiquitination assays, functional cell migration and invasion assays","journal":"Heliyon","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single Co-IP with functional overexpression assays, single lab, limited mechanistic detail in abstract","pmids":["39315162"],"is_preprint":false},{"year":2021,"finding":"Intestinal-specific transcription factor AhR binds the Ikzf3 locus, increases chromatin accessibility at an intestinal ILC2-specific open chromatin region, and promotes Ikzf3 transcription by enhancing H3K27ac, establishing AhR as an upstream regulator of Aiolos expression in intestinal ILC2s.","method":"ChIP (AhR binding at Ikzf3 locus), ATAC-seq (chromatin accessibility), H3K27ac ChIP-seq, gene expression analysis","journal":"Mucosal immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with epigenetic marks demonstrating direct regulation, single lab","pmids":["34349237"],"is_preprint":false}],"current_model":"IKZF3 (Aiolos) is a lymphoid zinc finger transcription factor that functions primarily as a transcriptional repressor by recruiting HDAC complexes (via mSin3 and NuRD) to silence target genes including IL-2, c-Myc, surrogate light chain genes, p66Shc, and interferon-stimulated genes; it heterodimerizes with Ikaros to cooperatively regulate lymphocyte development, and its subcellular localization and activity are modulated by IL-2-induced tyrosine phosphorylation and by PBK/TOPK-mediated phosphorylation during mitosis; its protein stability is regulated by the CRBN-CRL4 E3 ubiquitin ligase (which mediates IMiD/CELMoD drug-induced degradation) and by the deubiquitinase OTUB1; disease-associated missense variants in its DNA-binding domain (ZF2-3) cause dominant-negative interference with IKAROS through altered heterodimer DNA binding specificity, while haploinsufficiency variants in ZF5-6 or the stability domain impair lymphocyte development and humoral immunity."},"narrative":{"mechanistic_narrative":"IKZF3 (Aiolos) is a lymphoid zinc finger transcription factor that acts predominantly as a sequence-specific transcriptional repressor governing lymphocyte development, differentiation, and activation [PMID:39179932, PMID:22751139]. It heterodimerizes with Ikaros, and homo- versus heteromeric complexes carry distinct transcriptional activities, with dominant-negative Ikaros isoforms interfering with Aiolos function [PMID:9155026]. Repression is executed through two repression domains that recruit mSin3 and the NuRD nucleosome-remodeling/deacetylase machinery to drive promoter histone deacetylation, and is relieved by HDAC inhibitors [PMID:10357820, PMID:30228232]. Aiolos directly binds and silences a defined target set including the surrogate light chain genes Igll1/Vpreb1, c-Myc, Il2, and interferon-stimulated genes such as CD38, thereby enforcing cell-cycle withdrawal and developmental checkpoints [PMID:39179932, PMID:20566697, PMID:22751139, PMID:30228232]. DNA binding requires intact zinc-finger residues (N160) and directs the protein to pericentromeric heterochromatin [PMID:31251838, PMID:34155405]. Across lineages it shapes B cell development and high-affinity plasma cell generation, NK cell maturation, TH17, TFH, CD4/CD8 cytotoxic and virtual-memory programming, and tissue lymphocyte restraint, often by co-opting or antagonizing STAT5/STAT1 activity at target loci [PMID:14718515, PMID:25319415, PMID:38182668, PMID:36964178, PMID:38049581]. Aiolos protein abundance is controlled by the CRBN-CRL4 E3 ubiquitin ligase, which mediates IMiD/CELMoD drug-induced ubiquitination and proteasomal degradation [PMID:24292625, PMID:24328678, PMID:28425720], and its chromatin association is dynamically regulated by phosphorylation, including PBK/TOPK-mediated eviction during mitosis [PMID:40987773]. Heterozygous missense variants in the DNA-binding zinc fingers cause disease through dominant-negative heterodimeric interference with IKAROS, altering DNA-binding specificity to drive immunodeficiency and CLL-like malignancy, whereas variants affecting dimerization or the stability domain cause haploinsufficiency [PMID:34155405, PMID:33689703, PMID:34694366, PMID:38015619].","teleology":[{"year":1997,"claim":"Established Aiolos as an Ikaros-family partner whose transcriptional output depends on the composition of its dimeric complexes, defining the combinatorial logic of the family.","evidence":"Molecular cloning with heterodimerization and transcriptional activity assays","pmids":["9155026"],"confidence":"High","gaps":["Did not define DNA target sequences","Did not identify co-repressor machinery"]},{"year":1999,"claim":"Defined the molecular mechanism of repression by linking Aiolos/Ikaros repression domains to mSin3-HDAC recruitment and promoter histone deacetylation.","evidence":"In vivo/in vitro Co-IP, HDAC inhibitor treatment, and histone acetylation assays","pmids":["10357820"],"confidence":"High","gaps":["Did not map endogenous target genes","Did not address NuRD versus mSin3 selectivity"]},{"year":1998,"claim":"Demonstrated through genetic ablation that Aiolos negatively regulates BCR signaling and is required for specific peripheral B cell populations, anchoring its physiological role in B lymphocytes.","evidence":"Aiolos-null mouse with BCR stimulation, flow cytometry, and immunization","pmids":["9806640"],"confidence":"High","gaps":["Did not identify direct target genes underlying the phenotype","Cell-intrinsic versus extrinsic contribution not resolved here"]},{"year":2008,"claim":"Identified direct developmental targets, showing Aiolos enforces the pre-B checkpoint by silencing and repositioning surrogate light chain genes, later confirmed by acute degradation/ChIP-seq.","evidence":"Aiolos/OBF-1 double-KO mice, FISH repositioning, and auxin-inducible degron with ChIP-seq","pmids":["18974788","39179932","17971486"],"confidence":"High","gaps":["Mechanism of locus repositioning incompletely defined","Relative contribution of OBF-1 antagonism versus direct repression"]},{"year":2010,"claim":"Connected Aiolos repressor activity to proliferative control by showing direct binding and suppression of the c-Myc promoter precedes cell-cycle exit.","evidence":"ChIP and gain/loss-of-function in pre-B cells","pmids":["20566697"],"confidence":"High","gaps":["Co-repressor complex at the c-Myc promoter not specified","Direct versus indirect p27/cyclin D3 effects"]},{"year":2012,"claim":"Extended the repressor model to T helper differentiation by identifying upstream inducers (STAT3/AhR) and a direct Il2 silencing event driving TH17 fate.","evidence":"Aiolos-deficient mice with TH17 differentiation and Il2 chromatin analysis","pmids":["22751139"],"confidence":"High","gaps":["Genome-wide TH17 target set not fully defined","Co-repressor recruitment in T cells not addressed"]},{"year":2013,"claim":"Revealed that IMiD drugs act by hijacking the CRBN-CRL4 ligase to ubiquitinate and degrade Aiolos, explaining their anti-tumor and immunomodulatory effects.","evidence":"Quantitative proteomics, ubiquitination assays, and mutagenesis-based rescue","pmids":["24292625","24328678"],"confidence":"High","gaps":["Degron structural basis not yet defined in these studies","Downstream transcriptional consequences of degradation not fully mapped"]},{"year":2017,"claim":"Provided the structural and kinetic basis for differential drug-induced degradation, with crystallography of cereblon-compound complexes and rate-of-degradation correlations to efficacy.","evidence":"X-ray crystallography of cereblon-DDB1-CC-220 plus kinetic degradation assays","pmids":["28425720","26430725"],"confidence":"High","gaps":["Full Aiolos degron contacts not resolved in the structure","In vivo kinetics in patients not addressed"]},{"year":2018,"claim":"Showed Aiolos loss alone recapitulates IMiD effects in myeloma and that Aiolos/Ikaros repress interferon-stimulated genes (including CD38) via NuRD, linking degradation to an interferon-like death program.","evidence":"CRISPR knockout, RNA-seq, NuRD Co-IP, and CD38/ADCC assays","pmids":["30228232"],"confidence":"High","gaps":["Direct versus indirect ISG regulation not fully separated","NuRD subunit selectivity not defined"]},{"year":2021,"claim":"Defined the disease mechanism of zinc-finger missense variants as dominant-negative heterodimeric interference that redirects DNA binding, causing immunodeficiency and CLL-like malignancy.","evidence":"Knockin and conditional knockin mouse models with ChIP-seq, DNA binding, and dimerization-deficient rescue","pmids":["34155405","33689703","34694366"],"confidence":"High","gaps":["Why specific neomorphic genomic sites are bound is unresolved","Penetrance determinants of malignancy unknown"]},{"year":2024,"claim":"Defined post-translational and domain-level control of Aiolos: PBK/TOPK phosphorylation evicts it from mitotic chromosomes, and ZF5-6/stability-domain variants cause haploinsufficiency, distinguishing dominant-negative from loss-of-expression mechanisms.","evidence":"Pbk-/- mice with chromatin proteomics/ATAC-seq, and patient variant biochemistry/stability assays","pmids":["40987773","38015619"],"confidence":"Medium","gaps":["Functional consequence of mitotic eviction for gene expression not fully traced","OTUB1-mediated stabilization (#36) rests on a single low-confidence Co-IP"]},{"year":2024,"claim":"Broadened the lineage role of Aiolos by showing it binds AP-1 factors and balances STAT5/STAT1-driven programs across NK, CD4-CTL, virtual-memory, and tissue lymphocytes, acting as a node that tunes cytokine responsiveness.","evidence":"Conditional double KO with ChIP, plus multiple Ikzf3-/- models with ChIP for STAT occupancy","pmids":["38182668","36964178","41392082","38049581","38363226","39560988"],"confidence":"High","gaps":["Whether STAT antagonism is via direct competition or chromatin closure varies by locus","Co-repressor requirement in these contexts not uniformly tested"]},{"year":null,"claim":"How the choice between canonical repression complexes (mSin3 vs NuRD), neomorphic DNA targeting by mutants, and lineage-specific STAT partnering is mechanistically selected remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of Aiolos-DNA or Aiolos-co-repressor complexes","Rules governing context-specific target selection unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,4,11,33]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[18,24,33]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[4,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[21,24]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[21,24,29]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,11,33]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,8,12,26]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,17,29,34]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0,1,16]}],"complexes":["NuRD complex","mSin3-HDAC co-repressor complex","CRL4(CRBN) E3 ubiquitin ligase (substrate)"],"partners":["IKZF1","CRBN","PRDM1","PBK","OTUB1","STAT5","STAT1","POU2AF1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9UKT9","full_name":"Zinc finger protein Aiolos","aliases":["Ikaros family zinc finger protein 3"],"length_aa":509,"mass_kda":58.0,"function":"Transcription factor that plays an important role in the regulation of lymphocyte differentiation. Plays an essential role in regulation of B-cell differentiation, proliferation and maturation to an effector state. Involved in regulating BCL2 expression and controlling apoptosis in T-cells in an IL2-dependent manner","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q9UKT9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IKZF3","classification":"Not Classified","n_dependent_lines":39,"n_total_lines":1208,"dependency_fraction":0.03228476821192053},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IKZF3","total_profiled":1310},"omim":[{"mim_id":"621233","title":"IMMUNODYSREGULATION WITH VARIABLE IMMUNODEFICIENCY AND AUTOIMMUNITY; IMDIA","url":"https://www.omim.org/entry/621233"},{"mim_id":"619437","title":"IMMUNODEFICIENCY 84; IMD84","url":"https://www.omim.org/entry/619437"},{"mim_id":"619408","title":"TRIPARTITE MOTIF-CONTAINING PROTEIN 65; TRIM65","url":"https://www.omim.org/entry/619408"},{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"611403","title":"ASTHMA-RELATED TRAITS, SUSCEPTIBILITY TO, 6","url":"https://www.omim.org/entry/611403"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":11.1},{"tissue":"lymphoid tissue","ntpm":38.4}],"url":"https://www.proteinatlas.org/search/IKZF3"},"hgnc":{"alias_symbol":["Aiolos"],"prev_symbol":["ZNFN1A3"]},"alphafold":{"accession":"Q9UKT9","domains":[{"cath_id":"3.30.160.60","chopping":"118-171","consensus_level":"medium","plddt":74.2569,"start":118,"end":171},{"cath_id":"-","chopping":"202-264","consensus_level":"high","plddt":67.5256,"start":202,"end":264},{"cath_id":"-","chopping":"439-507","consensus_level":"medium","plddt":54.8129,"start":439,"end":507}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UKT9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UKT9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9UKT9-F1-predicted_aligned_error_v6.png","plddt_mean":47.91},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IKZF3","jax_strain_url":"https://www.jax.org/strain/search?query=IKZF3"},"sequence":{"accession":"Q9UKT9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9UKT9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9UKT9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9UKT9"}},"corpus_meta":[{"pmid":"24292625","id":"PMC_24292625","title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.","date":"2013","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24292625","citation_count":1492,"is_preprint":false},{"pmid":"24328678","id":"PMC_24328678","title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).","date":"2013","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/24328678","citation_count":524,"is_preprint":false},{"pmid":"9155026","id":"PMC_9155026","title":"Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9155026","citation_count":317,"is_preprint":false},{"pmid":"9806640","id":"PMC_9806640","title":"Aiolos regulates B cell activation and maturation to effector state.","date":"1998","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9806640","citation_count":262,"is_preprint":false},{"pmid":"10357820","id":"PMC_10357820","title":"Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10357820","citation_count":259,"is_preprint":false},{"pmid":"11371362","id":"PMC_11371362","title":"The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21.","date":"2001","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11371362","citation_count":258,"is_preprint":false},{"pmid":"28425720","id":"PMC_28425720","title":"A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.","date":"2017","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28425720","citation_count":217,"is_preprint":false},{"pmid":"22751139","id":"PMC_22751139","title":"Aiolos promotes TH17 differentiation by directly silencing Il2 expression.","date":"2012","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22751139","citation_count":215,"is_preprint":false},{"pmid":"26430725","id":"PMC_26430725","title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.","date":"2015","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/26430725","citation_count":189,"is_preprint":false},{"pmid":"22464253","id":"PMC_22464253","title":"Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22464253","citation_count":156,"is_preprint":false},{"pmid":"14718515","id":"PMC_14718515","title":"Aiolos is required for the generation of high affinity bone marrow plasma cells responsible for long-term immunity.","date":"2004","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14718515","citation_count":118,"is_preprint":false},{"pmid":"12752680","id":"PMC_12752680","title":"Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies.","date":"2003","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12752680","citation_count":114,"is_preprint":false},{"pmid":"20566697","id":"PMC_20566697","title":"Ikaros and Aiolos inhibit pre-B-cell proliferation by directly suppressing c-Myc expression.","date":"2010","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/20566697","citation_count":106,"is_preprint":false},{"pmid":"17971486","id":"PMC_17971486","title":"Interferon regulatory factors 4 and 8 induce the expression of Ikaros and Aiolos to down-regulate pre-B-cell receptor and promote cell-cycle withdrawal in pre-B-cell development.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17971486","citation_count":91,"is_preprint":false},{"pmid":"30228232","id":"PMC_30228232","title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30228232","citation_count":79,"is_preprint":false},{"pmid":"10369681","id":"PMC_10369681","title":"Aiolos transcription factor controls cell death in T cells by regulating Bcl-2 expression and its cellular localization.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10369681","citation_count":78,"is_preprint":false},{"pmid":"31151137","id":"PMC_31151137","title":"Suppression of Aiolos and Ikaros expression by lenalidomide reduces human ILC3-ILC1/NK cell transdifferentiation.","date":"2019","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31151137","citation_count":76,"is_preprint":false},{"pmid":"25319415","id":"PMC_25319415","title":"Peripheral natural killer cell maturation depends on the transcription factor Aiolos.","date":"2014","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/25319415","citation_count":72,"is_preprint":false},{"pmid":"24823637","id":"PMC_24823637","title":"Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells.","date":"2014","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/24823637","citation_count":72,"is_preprint":false},{"pmid":"11997672","id":"PMC_11997672","title":"Aiolos and Ikaros: regulators of lymphocyte development, homeostasis and lymphoproliferation.","date":"2002","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/11997672","citation_count":68,"is_preprint":false},{"pmid":"25610725","id":"PMC_25610725","title":"Lenalidomide induces degradation of IKZF1 and IKZF3.","date":"2014","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/25610725","citation_count":66,"is_preprint":false},{"pmid":"29945920","id":"PMC_29945920","title":"Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.","date":"2018","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/29945920","citation_count":63,"is_preprint":false},{"pmid":"37922905","id":"PMC_37922905","title":"Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence.","date":"2023","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/37922905","citation_count":61,"is_preprint":false},{"pmid":"28358507","id":"PMC_28358507","title":"Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.","date":"2017","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28358507","citation_count":57,"is_preprint":false},{"pmid":"24068664","id":"PMC_24068664","title":"Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24068664","citation_count":55,"is_preprint":false},{"pmid":"34155405","id":"PMC_34155405","title":"A variant in human AIOLOS impairs adaptive immunity by interfering with IKAROS.","date":"2021","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34155405","citation_count":54,"is_preprint":false},{"pmid":"12574333","id":"PMC_12574333","title":"Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12574333","citation_count":51,"is_preprint":false},{"pmid":"33689703","id":"PMC_33689703","title":"A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.","date":"2021","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/33689703","citation_count":50,"is_preprint":false},{"pmid":"35895319","id":"PMC_35895319","title":"Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35895319","citation_count":46,"is_preprint":false},{"pmid":"28848067","id":"PMC_28848067","title":"Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28848067","citation_count":43,"is_preprint":false},{"pmid":"34687790","id":"PMC_34687790","title":"IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34687790","citation_count":40,"is_preprint":false},{"pmid":"34694366","id":"PMC_34694366","title":"T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34694366","citation_count":40,"is_preprint":false},{"pmid":"17646674","id":"PMC_17646674","title":"Combinatorial effects of splice variants modulate function of Aiolos.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/17646674","citation_count":39,"is_preprint":false},{"pmid":"33499314","id":"PMC_33499314","title":"Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33499314","citation_count":37,"is_preprint":false},{"pmid":"21139082","id":"PMC_21139082","title":"Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21139082","citation_count":37,"is_preprint":false},{"pmid":"28241063","id":"PMC_28241063","title":"Role of DNA methylation in expression control of the IKZF3-GSDMA region in human epithelial cells.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28241063","citation_count":36,"is_preprint":false},{"pmid":"34349237","id":"PMC_34349237","title":"Tissue signals imprint Aiolos expression in ILC2s to modulate type 2 immunity.","date":"2021","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34349237","citation_count":29,"is_preprint":false},{"pmid":"25446972","id":"PMC_25446972","title":"Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells.","date":"2015","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25446972","citation_count":28,"is_preprint":false},{"pmid":"18184862","id":"PMC_18184862","title":"The Aiolos transcription factor is up-regulated in chronic lymphocytic leukemia.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18184862","citation_count":28,"is_preprint":false},{"pmid":"29718735","id":"PMC_29718735","title":"Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.","date":"2018","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/29718735","citation_count":26,"is_preprint":false},{"pmid":"38182668","id":"PMC_38182668","title":"IKAROS and AIOLOS directly regulate AP-1 transcriptional complexes and are essential for NK cell development.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38182668","citation_count":25,"is_preprint":false},{"pmid":"26823144","id":"PMC_26823144","title":"Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.","date":"2016","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/26823144","citation_count":24,"is_preprint":false},{"pmid":"17523942","id":"PMC_17523942","title":"Aiolos controls gene conversion and cell death in DT40 B cells.","date":"2007","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17523942","citation_count":23,"is_preprint":false},{"pmid":"11714801","id":"PMC_11714801","title":"The association of Aiolos transcription factor and Bcl-xL is involved in the control of apoptosis.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11714801","citation_count":23,"is_preprint":false},{"pmid":"39179932","id":"PMC_39179932","title":"Transcriptional function of E2A, Ebf1, Pax5, Ikaros and Aiolos analyzed by in vivo acute protein degradation in early B cell development.","date":"2024","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39179932","citation_count":21,"is_preprint":false},{"pmid":"36964178","id":"PMC_36964178","title":"Aiolos represses CD4+ T cell cytotoxic programming via reciprocal regulation of TFH transcription factors and IL-2 sensitivity.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36964178","citation_count":21,"is_preprint":false},{"pmid":"32321757","id":"PMC_32321757","title":"IKZF3/Aiolos Is Associated with but Not Sufficient for the Expression of IL-10 by CD4+ T Cells.","date":"2020","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/32321757","citation_count":21,"is_preprint":false},{"pmid":"29510406","id":"PMC_29510406","title":"Polymorphisms of IKZF3 Gene and Autoimmune Thyroid Diseases: Associated with Graves' Disease but Not with Hashimoto's Thyroiditis.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29510406","citation_count":21,"is_preprint":false},{"pmid":"10552935","id":"PMC_10552935","title":"Human aiolos, an ikaros-related zinc finger DNA binding protein: cDNA cloning, tissue expression pattern, and chromosomal mapping.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10552935","citation_count":21,"is_preprint":false},{"pmid":"38049581","id":"PMC_38049581","title":"The transcription factor Aiolos restrains the activation of intestinal intraepithelial lymphocytes.","date":"2023","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38049581","citation_count":18,"is_preprint":false},{"pmid":"19540588","id":"PMC_19540588","title":"Differential aiolos expression in human hematopoietic subpopulations.","date":"2009","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/19540588","citation_count":18,"is_preprint":false},{"pmid":"25271777","id":"PMC_25271777","title":"Association between polymorphisms of the IKZF3 gene and systemic lupus erythematosus in a Chinese Han population.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25271777","citation_count":18,"is_preprint":false},{"pmid":"33727237","id":"PMC_33727237","title":"Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus.","date":"2021","source":"Lupus science & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33727237","citation_count":18,"is_preprint":false},{"pmid":"34265590","id":"PMC_34265590","title":"Inborn errors of IKAROS and AIOLOS.","date":"2021","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34265590","citation_count":17,"is_preprint":false},{"pmid":"30816208","id":"PMC_30816208","title":"Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30816208","citation_count":17,"is_preprint":false},{"pmid":"18974788","id":"PMC_18974788","title":"Silencing and nuclear repositioning of the lambda5 gene locus at the pre-B cell stage requires Aiolos and OBF-1.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18974788","citation_count":17,"is_preprint":false},{"pmid":"30338042","id":"PMC_30338042","title":"Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30338042","citation_count":17,"is_preprint":false},{"pmid":"10508239","id":"PMC_10508239","title":"The evolutionarily conserved avian Aiolos gene encodes alternative isoforms.","date":"1999","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10508239","citation_count":15,"is_preprint":false},{"pmid":"27080863","id":"PMC_27080863","title":"Allelic imbalance of multiple sclerosis susceptibility genes IKZF3 and IQGAP1 in human peripheral blood.","date":"2016","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27080863","citation_count":14,"is_preprint":false},{"pmid":"19427336","id":"PMC_19427336","title":"Lacking of Aiolos accelerates pre-mature B cell apoptosis mediated by BCR signaling through elevation in cytochrome c release.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19427336","citation_count":14,"is_preprint":false},{"pmid":"11745366","id":"PMC_11745366","title":"Both normal and leukemic B lymphocytes express multiple isoforms of the human Aiolos gene.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11745366","citation_count":14,"is_preprint":false},{"pmid":"38015619","id":"PMC_38015619","title":"Disease-associated AIOLOS variants lead to immune deficiency/dysregulation by haploinsufficiency and redefine AIOLOS functional domains.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38015619","citation_count":13,"is_preprint":false},{"pmid":"29729093","id":"PMC_29729093","title":"Baicalein Inhibits Proliferation of Myeloma U266 Cells by Downregulating IKZF1 and IKZF3.","date":"2018","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/29729093","citation_count":13,"is_preprint":false},{"pmid":"35444653","id":"PMC_35444653","title":"AIOLOS Variants Causing Immunodeficiency in Human and Mice.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35444653","citation_count":12,"is_preprint":false},{"pmid":"26546109","id":"PMC_26546109","title":"Overexpression of Aiolos in Peripheral Blood Mononuclear Cell Subsets from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis.","date":"2015","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26546109","citation_count":12,"is_preprint":false},{"pmid":"34341502","id":"PMC_34341502","title":"Aiolos regulates eosinophil migration into tissues.","date":"2021","source":"Mucosal immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34341502","citation_count":11,"is_preprint":false},{"pmid":"39054911","id":"PMC_39054911","title":"Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.","date":"2024","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/39054911","citation_count":11,"is_preprint":false},{"pmid":"24399134","id":"PMC_24399134","title":"Overexpression of AIOLOS inhibits cell proliferation and suppresses apoptosis in Nalm-6 cells.","date":"2013","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24399134","citation_count":11,"is_preprint":false},{"pmid":"27308319","id":"PMC_27308319","title":"Aiolos and Lymphocyte Mimicry in Lung Cancer.","date":"2014","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308319","citation_count":11,"is_preprint":false},{"pmid":"17376390","id":"PMC_17376390","title":"Aiolos: an ungrateful member of the Ikaros family.","date":"2007","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17376390","citation_count":11,"is_preprint":false},{"pmid":"38773004","id":"PMC_38773004","title":"AIOLOS-Associated Inborn Errors of Immunity.","date":"2024","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38773004","citation_count":10,"is_preprint":false},{"pmid":"36525791","id":"PMC_36525791","title":"IKZF3 modulates cerebral ischemia/reperfusion injury by inhibiting neuroinflammation.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36525791","citation_count":10,"is_preprint":false},{"pmid":"26645971","id":"PMC_26645971","title":"Ikaros, Helios, and Aiolos protein levels increase in human thymocytes after β selection.","date":"2016","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/26645971","citation_count":10,"is_preprint":false},{"pmid":"26185311","id":"PMC_26185311","title":"Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients.","date":"2015","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26185311","citation_count":10,"is_preprint":false},{"pmid":"32766436","id":"PMC_32766436","title":"Urinary Cell Transcriptome Profiling and Identification of ITM2A, SLAMF6, and IKZF3 as Biomarkers of Acute Rejection in Human Kidney Allografts.","date":"2020","source":"Transplantation direct","url":"https://pubmed.ncbi.nlm.nih.gov/32766436","citation_count":9,"is_preprint":false},{"pmid":"38610997","id":"PMC_38610997","title":"Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38610997","citation_count":8,"is_preprint":false},{"pmid":"36180600","id":"PMC_36180600","title":"IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.","date":"2022","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36180600","citation_count":8,"is_preprint":false},{"pmid":"12445735","id":"PMC_12445735","title":"Quantification of human Aiolos splice variants by real-time PCR.","date":"2002","source":"Journal of immunological methods","url":"https://pubmed.ncbi.nlm.nih.gov/12445735","citation_count":8,"is_preprint":false},{"pmid":"31251838","id":"PMC_31251838","title":"N160 of Aiolos Determines its DNA-Binding Activity.","date":"2019","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/31251838","citation_count":7,"is_preprint":false},{"pmid":"36353107","id":"PMC_36353107","title":"Novel IKZF3 transcriptomic signature correlates with positive outcomes of skin cutaneous melanoma: A pan-cancer analysis.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36353107","citation_count":7,"is_preprint":false},{"pmid":"39560988","id":"PMC_39560988","title":"Aiolos promotes CXCR3 expression on Th1 cells via positive regulation of IFN-γ/STAT1 signaling.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/39560988","citation_count":6,"is_preprint":false},{"pmid":"37662955","id":"PMC_37662955","title":"Impaired tissue homing by the Ikzf3N159S variant is mediated by interfering with Ikaros function.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37662955","citation_count":6,"is_preprint":false},{"pmid":"18206652","id":"PMC_18206652","title":"Differential epigenetic regulation of Aiolos expression in human tumoral cell lines and primary cells.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18206652","citation_count":6,"is_preprint":false},{"pmid":"25524659","id":"PMC_25524659","title":"Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells.","date":"2014","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25524659","citation_count":5,"is_preprint":false},{"pmid":"38018448","id":"PMC_38018448","title":"IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children.","date":"2023","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38018448","citation_count":4,"is_preprint":false},{"pmid":"38363226","id":"PMC_38363226","title":"Cytotoxic Programming of CD4+ T Cells Is Regulated by Opposing Actions of the Related Transcription Factors Eos and Aiolos.","date":"2024","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/38363226","citation_count":4,"is_preprint":false},{"pmid":"40817326","id":"PMC_40817326","title":"Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma.","date":"2025","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/40817326","citation_count":3,"is_preprint":false},{"pmid":"34105458","id":"PMC_34105458","title":"[Relationship between IKZF3 Gene Single Nucleotide Polymorphisms and Childhood Acute Lymphoblastic Leukemia].","date":"2021","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/34105458","citation_count":3,"is_preprint":false},{"pmid":"32591583","id":"PMC_32591583","title":"Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32591583","citation_count":3,"is_preprint":false},{"pmid":"38758229","id":"PMC_38758229","title":"Identification and Functional Analysis of a de novo IKZF3 Mutation in a Pediatric Patient with Combined Immunodeficiency.","date":"2024","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38758229","citation_count":2,"is_preprint":false},{"pmid":"11173542","id":"PMC_11173542","title":"Genetic mapping and allelic loss analysis in mouse thymic lymphomas of Helios and Aiolos belonging to the Ikaros gene family.","date":"2001","source":"Japanese journal of cancer research : Gann","url":"https://pubmed.ncbi.nlm.nih.gov/11173542","citation_count":2,"is_preprint":false},{"pmid":"27453112","id":"PMC_27453112","title":"[Association between IKZF3 gene polymorphisms and systemic lupus erythematosus in Han ethnic group in southern China: a case-control study].","date":"2016","source":"Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi","url":"https://pubmed.ncbi.nlm.nih.gov/27453112","citation_count":2,"is_preprint":false},{"pmid":"17296582","id":"PMC_17296582","title":"A search for a mutation of the Aiolos phosphorylation domain in lymphocytes from patients with leukemia.","date":"2007","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/17296582","citation_count":2,"is_preprint":false},{"pmid":"31974483","id":"PMC_31974483","title":"Author Correction: Overexpression of Aiolos promotes epithelial-mesenchymal transition and cancer stem cell-like properties in lung cancer cells.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31974483","citation_count":2,"is_preprint":false},{"pmid":"38489359","id":"PMC_38489359","title":"Kidins220 and Aiolos promote thymic iNKT cell development by reducing TCR signals.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/38489359","citation_count":1,"is_preprint":false},{"pmid":"41392082","id":"PMC_41392082","title":"Aiolos restricts the generation of antigen-inexperienced, virtual memory CD8+ T cells in mice.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41392082","citation_count":1,"is_preprint":false},{"pmid":"39902962","id":"PMC_39902962","title":"Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir.","date":"2025","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/39902962","citation_count":1,"is_preprint":false},{"pmid":"39315162","id":"PMC_39315162","title":"Exploring the oncogenic potential of Aiolos in lung cancer through OTUB1-mediated ubiquitination.","date":"2024","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/39315162","citation_count":1,"is_preprint":false},{"pmid":"40987773","id":"PMC_40987773","title":"PBK/TOPK mediates Ikaros, Aiolos and CTCF displacement from mitotic chromosomes and alters chromatin accessibility at selected C2H2-zinc finger protein binding sites.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40987773","citation_count":1,"is_preprint":false},{"pmid":"25608224","id":"PMC_25608224","title":"Overexpression of Aiolos in Nalm-6 acute lymphoblastic leukaemia cells reduces apoptosis by suppressing phosphatase and tensin homologue deleted on chromosome 10 and activating the phosphatidylinositol-3-kinase/Akt signalling pathway.","date":"2015","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/25608224","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47080,"output_tokens":8993,"usd":0.138068,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19058,"output_tokens":4120,"usd":0.099145,"stage2_stop_reason":"end_turn"},"total_usd":0.237213,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"Lenalidomide causes selective ubiquitination and degradation of IKZF3 (Aiolos) by the CRBN-CRL4 E3 ubiquitin ligase complex; a single amino acid substitution in IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth. IKZF3 degradation also mediates lenalidomide-induced IL-2 production in T cells.\",\n      \"method\": \"Quantitative proteomics, ubiquitination assays, mutagenesis (single amino acid substitution), cell growth rescue experiments\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — quantitative proteomics combined with mutagenesis and functional rescue, replicated across multiple studies\",\n      \"pmids\": [\"24292625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Lenalidomide and pomalidomide induce interaction of IKZF3 (Aiolos) with CRL4(CRBN), promoting IKZF3 binding to the complex, enhanced ubiquitination, and cereblon-dependent proteasomal degradation in T lymphocytes. IKZF3 and IKZF1 function as transcriptional repressors of IL-2 expression.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, Western blot, flow cytometry, reporter gene assays\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, multiple orthogonal methods, independently replicates PMID 24292625\",\n      \"pmids\": [\"24328678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"IKZF3 (Aiolos) heterodimerizes with Ikaros proteins; mutant dominant-negative Ikaros isoforms interfere with Aiolos activity, demonstrating functional interdependence. Aiolos homo- and heteromeric complexes with Ikaros have distinct relative transcriptional activities.\",\n      \"method\": \"Molecular cloning, protein interaction studies (heterodimerization assays), transcriptional activity assays, expression analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct heterodimerization demonstrated biochemically with functional validation, foundational study replicated widely\",\n      \"pmids\": [\"9155026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Aiolos-null B cells exhibit augmented BCR-mediated proliferative responses and an activated surface phenotype, establishing Aiolos as a negative regulator of BCR signaling and B cell activation. Peritoneal, marginal zone, and recirculating bone marrow B cell populations are greatly reduced in Aiolos-deficient mice.\",\n      \"method\": \"Aiolos-null mouse model, in vitro BCR stimulation proliferation assays, flow cytometry, in vivo immunization\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic null model with defined cellular phenotype, multiple orthogonal readouts\",\n      \"pmids\": [\"9806640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Ikaros and Aiolos function as transcriptional repressors through two repression domains; repression correlates with histone deacetylation at promoters and is relieved by HDAC inhibitors. Ikaros/Aiolos repression domains interact in vivo and in vitro with mSin3 co-repressors that bind HDACs.\",\n      \"method\": \"Transcriptional repression assays, HDAC inhibitor treatment, histone acetylation assays (chromatin), co-immunoprecipitation (in vivo and in vitro)\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro and in vivo interaction assays combined with functional histone modification readouts, replicated\",\n      \"pmids\": [\"10357820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Aiolos interacts with Ras in T cells; IL-2 controls subcellular distribution of Aiolos and induces its tyrosine phosphorylation, required for dissociation from Ras. Aiolos binds functional sites in the Bcl-2 promoter and activates Bcl-2 transcription, preventing apoptosis in IL-2-deprived cells.\",\n      \"method\": \"Co-immunoprecipitation (in vitro and in vivo), indirect immunofluorescence, promoter reporter (luciferase) assays, site-directed mutagenesis of Bcl-2 promoter, co-transfection experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple methods in one study including Co-IP, mutagenesis, and functional reporter assays, single lab\",\n      \"pmids\": [\"10369681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Aiolos associates with Bcl-xL in IL-4-stimulated T cells; IL-4 deprivation increases the Bcl-xL/Aiolos interaction. IL-4 induces tyrosine phosphorylation of Aiolos, required for dissociation from Bcl-xL. Cells overexpressing both Bcl-xL and Aiolos cannot block apoptosis, establishing Aiolos as a regulator of Bcl-xL anti-apoptotic function.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, indirect immunofluorescence, co-transfection overexpression experiments\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — yeast two-hybrid validated by Co-IP and functional assays, single lab\",\n      \"pmids\": [\"11714801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BCR signaling and MZ B cell development are regulated by Aiolos in epistasis with Btk and CD21; loss of Aiolos enhances follicular B cell maturation signals through a pathway requiring Btk, placing Btk downstream of (epistatic to) Aiolos.\",\n      \"method\": \"Genetic epistasis analysis using Aiolos-null, Btk-null, and CD21-null mouse models\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with multiple null mouse models, single study\",\n      \"pmids\": [\"11371362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Aiolos is specifically required (in a B cell-intrinsic manner demonstrated by chimera reconstitution) for the generation of high-affinity bone marrow plasma cells responsible for long-term immunity, without affecting somatic hypermutation, memory B cells, or short-lived splenic plasma cells.\",\n      \"method\": \"Aiolos-null mouse model, bone marrow chimera reconstitution, serum antibody titer measurement, immunization with hapten concentrations\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — chimera reconstitution establishes B cell-intrinsic requirement, multiple orthogonal readouts\",\n      \"pmids\": [\"14718515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Aiolos and Ikaros directly bind the c-Myc promoter in pre-B cells in vivo and suppress c-Myc expression. Downregulation of c-Myc is required for the growth-inhibitory effect of Aiolos/Ikaros and precedes p27 induction and cyclin D3 downregulation, establishing c-Myc as a direct downstream target.\",\n      \"method\": \"ChIP (chromatin immunoprecipitation), gene expression analysis, gain/loss-of-function in pre-B cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter binding plus functional epistasis experiments, single lab with multiple methods\",\n      \"pmids\": [\"20566697\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IRF4 and IRF8 induce Aiolos expression in pre-B cells; reconstitution of Aiolos (or Ikaros) expression is sufficient to suppress surrogate light chain expression and down-regulate pre-BCR in cells lacking IRF4/8. Aiolos is required downstream of IRF4/8 for cell-cycle withdrawal.\",\n      \"method\": \"Gain- and loss-of-function experiments in pre-B cells, gene expression analysis, cell cycle analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution and loss-of-function experiments establishing pathway position, single lab\",\n      \"pmids\": [\"17971486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Under TH17-polarizing conditions, STAT3 and AhR upregulate Aiolos expression. Aiolos directly silences the Il2 locus, promoting TH17 differentiation in vitro and in vivo, demonstrated using Aiolos-deficient mice.\",\n      \"method\": \"Aiolos-deficient mouse model, in vitro and in vivo TH17 differentiation assays, chromatin analysis of Il2 locus\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic null model with in vitro and in vivo validation, upstream regulators identified\",\n      \"pmids\": [\"22751139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Aiolos is required for peripheral NK cell maturation; Aiolos expression is initiated at NK lineage commitment. Loss of Aiolos causes a block in CD11b(high)CD27(-) NK cell maturation intrinsic to the NK lineage, and genetic analysis revealed Aiolos acts independently of T-bet and Blimp1.\",\n      \"method\": \"Aiolos-null mouse model, flow cytometry of NK maturation stages, cell surface marker analysis, genetic epistasis with T-bet and Blimp1 null mice, NK cell tumor and viral infection models\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic null plus epistasis with multiple other TF knockouts, intrinsic defect demonstrated\",\n      \"pmids\": [\"25319415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Aiolos reconfigures chromatin structure within the SHC1 gene, causing isoform-specific silencing of p66Shc (an anchorage reporter), blocking anoikis. Aiolos also decreases expression of adhesion-related genes, disrupting cell-cell and cell-matrix interactions in cancer cells.\",\n      \"method\": \"Chromatin analysis (epigenetic assays), gene expression profiling, anoikis assays in vitro and in vivo (xenograft)\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromatin remodeling and functional anoikis assays, single lab, multiple methods\",\n      \"pmids\": [\"24823637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The rate (half-maximal rate) of CRL4(CRBN)-dependent Aiolos and Ikaros degradation—not the final extent—correlates with the relative anti-proliferative efficacy of lenalidomide vs. pomalidomide. Sequential downregulation of Aiolos/Ikaros → c-Myc → IRF4 is required for growth inhibition and apoptosis in MM cells.\",\n      \"method\": \"Kinetic degradation analysis, Western blot time course, cell growth inhibition and apoptosis assays\",\n      \"journal\": \"Blood cancer journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinetic analysis with multiple cell lines, single lab\",\n      \"pmids\": [\"26430725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Aiolos interacts with Blimp-1 in multiple myeloma cells (identified by mass spectrometry). Aiolos and Blimp-1 co-bind a large number of genomic targets including apoptosis-related genes. Aiolos promotes Blimp-1 binding to target genes and enhances Blimp-1-dependent transcriptional repression.\",\n      \"method\": \"Mass spectrometry (Aiolos-Blimp-1 interaction), ChIP-chip (genome-wide co-binding), transcriptome analysis, functional repression assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MS-identified interaction validated by ChIP with functional transcriptional readout, single lab\",\n      \"pmids\": [\"26823144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CC-220 (iberdomide) binds cereblon with higher affinity than lenalidomide or pomalidomide, resulting in more potent and extensive cellular degradation of Ikaros and Aiolos. Crystal structure of cereblon-DDB1-CC-220 complex reveals additional contacts between CC-220 and cereblon outside the modeled IKZF1/IKZF3 binding site that account for increased potency.\",\n      \"method\": \"Crystal structure (X-ray crystallography) of cereblon-DDB1-compound complex, binding affinity measurements, cellular degradation assays\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with functional degradation assays demonstrating structure-function relationship\",\n      \"pmids\": [\"28425720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRISPR-Cas9 deletion of IKZF3 (Aiolos) alone in MM cell lines recapitulates IMiD-induced cell cycle arrest and apoptosis. Aiolos/Ikaros repress interferon-stimulated genes (ISGs) including CD38 through interaction with the NuRD (nucleosome remodeling and deacetylase) complex, and their loss activates an interferon-like response that contributes to MM cell death and increases CD38 surface expression.\",\n      \"method\": \"CRISPR-Cas9 knockout, RNA-seq transcriptomics, co-immunoprecipitation (NuRD complex association), flow cytometry (CD38 surface expression), NK cell ADCC assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR knockout with multiple orthogonal functional readouts and Co-IP for NuRD interaction, single lab\",\n      \"pmids\": [\"30228232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A heterozygous IKZF3 missense variant (G→R in DNA-binding domain) causes mutant AIOLOS homodimers and AIOLOS-IKAROS heterodimers to fail binding the canonical DNA sequence. Instead, these dimers bind genomic regions lacking canonical motifs. Removal of the dimerization capacity from mutant AIOLOS restored B cell development, establishing that the dominance is due to heterodimeric interference with IKAROS function.\",\n      \"method\": \"Mouse knockin model (corresponding variant), DNA binding assays, ChIP-seq (altered genomic targeting), B cell development analysis, dimerization-deficient variant rescue experiments\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockin mouse model with DNA binding, ChIP-seq, and dimerization-deficient rescue experiments, multiple orthogonal methods\",\n      \"pmids\": [\"34155405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The IKZF3-L162R hotspot mutation alters DNA binding specificity and target gene selection, causing hyperactivation of BCR signaling and overexpression of NF-κB target genes, driving CLL-like disease in a conditional knockin mouse model (~40% penetrance).\",\n      \"method\": \"B cell-restricted conditional knockin mouse model, ChIP-seq (altered DNA binding), RNA-seq, BCR signaling assays (ibrutinib sensitivity)\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional knockin mouse model with ChIP-seq and signaling pathway validation, multiple orthogonal methods\",\n      \"pmids\": [\"33689703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AIOLOS p.N160S heterozygous variant causes dominant-negative impairment of B and T cell development; mutant protein fails DNA binding and pericentromeric targeting. The mutant has a dominant-negative effect over WT AIOLOS but not WT IKAROS.\",\n      \"method\": \"Patient analysis, in vitro DNA binding assays, pericentromeric targeting assays, murine model recapitulation\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro binding and localization assays with mouse model validation, single study\",\n      \"pmids\": [\"34694366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Full-length Aiolos isoforms localize to heterochromatin; different Aiolos isoforms arising from alternative splicing have distinct abilities to heterodimerize with Ikaros, associate with HDAC-containing complexes, and produce histone modifications. The cellular activities of Aiolos are dependent on combinations of functional domains determined by differential splicing.\",\n      \"method\": \"Cellular localization studies (immunofluorescence), co-immunoprecipitation (Ikaros heterodimerization, HDAC complex), histone modification assays, DNA-binding assays of isoforms\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple methods in single study examining isoform-specific functions, single lab\",\n      \"pmids\": [\"17646674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Aiolos and OBF-1 cooperate to silence lambda5 surrogate light chain gene expression and mediate its developmentally regulated nuclear repositioning at the pre-B cell stage; without both factors, lambda5 and VpreB fail to be efficiently silenced, and nuclear repositioning of lambda5 is impaired.\",\n      \"method\": \"Aiolos/OBF-1 double-knockout mouse model, gene expression analysis, nuclear repositioning assays (FISH), light chain rearrangement analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic model with nuclear localization readout and functional gene silencing validation, single lab\",\n      \"pmids\": [\"18974788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"OBF-1 is required for the SLE-like phenotypes in Aiolos-null mice; loss of OBF-1 reverses B cell hyperproliferation, activation marker overexpression, and spontaneous germinal center formation in Aiolos-null mice. The double-mutant mice show a block in pre-B to immature B cell transition, establishing that Aiolos suppresses OBF-1-dependent B cell activation.\",\n      \"method\": \"Aiolos/OBF-1 double-knockout mouse model, flow cytometry, B cell proliferation assays, antibody measurements\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with double-knockout model, multiple cellular phenotype readouts, single lab\",\n      \"pmids\": [\"12574333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"N160 is a key amino acid for IKZF3 DNA-binding activity; mutation of N160A results in loss of peripheral heterochromatin localization, dissociation from target genes, and inability to change target gene expression.\",\n      \"method\": \"Site-directed mutagenesis (N160A), immunofluorescence (heterochromatin localization), ChIP (target gene association), gene expression analysis\",\n      \"journal\": \"Anatomical record (Hoboken, N.J. : 2007)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis with multiple functional readouts (localization, ChIP, expression), single lab\",\n      \"pmids\": [\"31251838\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Aiolos deficiency results in reduced expression of key TFH transcription factors and reduced TFH differentiation during influenza infection, while CD4-CTL programming is elevated with enhanced Eomes and cytolytic molecule expression. Aiolos deficiency allows enhanced IL-2 sensitivity and increased STAT5 association with CD4-CTL gene targets including Eomes, effector molecules, and IL2Ra.\",\n      \"method\": \"Aiolos-deficient mouse model (influenza infection), flow cytometry, ChIP (STAT5 occupancy at CD4-CTL gene targets), gene expression analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null model with in vivo infection and ChIP for direct mechanism, single lab\",\n      \"pmids\": [\"36964178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IKZF1 (Ikaros) and IKZF3 (Aiolos) directly bind AP-1 family transcription factors; deletion of both Ikzf1 and Ikzf3 in NK cells results in further reduction of Jun/Fos expression and complete loss of peripheral NK cells. IKZF3 upregulation is observed in Ikzf1-null NK cells, indicating compensatory regulation.\",\n      \"method\": \"Conditional genetic inactivation in NK cells (Ikzf1 and Ikzf3 single and double conditional KO), ChIP (direct AP-1 binding), transcriptional analysis, flow cytometry\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional double KO with ChIP-demonstrated direct binding and functional NK cell phenotype, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"38182668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"AIOLOS zinc finger 5-6 domain is required for dimerization; a Q402* truncation mutant lacking ZF5-6 can still homodimerize with WT AIOLOS and negatively regulates DNA binding through ZF1 (a previously unrecognized function for this domain). An E82K variant leads to haploinsufficiency by affecting a protein stability domain.\",\n      \"method\": \"Patient variant analysis, in vitro DNA binding assays, pericentromeric targeting assays, transcriptome analysis, protein stability assays, homodimerization assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple biochemical assays defining domain function, single study with 3 families\",\n      \"pmids\": [\"38015619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Aiolos represses Eomes expression and the IL-15R subunit CD122 (CD8+ T cell virtual memory regulators); Aiolos-deficient mice show enhanced virtual memory CD8+ T cell frequency and function, establishing Aiolos as a molecular repressor of virtual memory T cell programming.\",\n      \"method\": \"Ikzf3-/- mouse model, flow cytometry, cytokine stimulation assays, gene expression analysis, influenza infection model\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null model with mechanistic targets (Eomes, CD122), single lab\",\n      \"pmids\": [\"41392082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PBK/TOPK mitotic kinase phosphorylates Aiolos (IKZF3) to promote its dissociation from chromosomes during mitosis; Aiolos is retained on mitotic chromosomes in Pbk-/- cells, and PBK inhibitor OTS514 rapidly reverses Aiolos eviction from chromosomes.\",\n      \"method\": \"Pbk-/- mouse model, mitotic chromosome fractionation proteomics, immunofluorescence, PBK inhibitor (OTS514) treatment, ATAC-seq (chromatin accessibility)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null plus pharmacological inhibition with proteomics and functional chromatin readouts, single lab\",\n      \"pmids\": [\"40987773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Aiolos promotes CXCR3 expression on Th1 cells by sustaining expression of JAK2 and STAT1; Aiolos deficiency reduces STAT1 tyrosine phosphorylation and STAT1 enrichment at the Cxcr3 promoter. Aiolos and STAT1 form a positive feedback loop via reciprocal regulation downstream of IFN-γ signaling.\",\n      \"method\": \"Aiolos-deficient mouse model (influenza infection), ChIP (STAT1 at Cxcr3 promoter), flow cytometry (phospho-STAT1), gene expression analysis\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null model with ChIP for direct promoter occupancy, single lab\",\n      \"pmids\": [\"39560988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Aiolos is a downstream effector of Kidins220 during thymic iNKT cell development. Aiolos expression is downregulated in Kidins220-deficient iNKT cells, and Aiolos KO phenocopies enhanced apoptosis at iNKT stages 2 and 3, placing Aiolos downstream of Kidins220 in this pathway.\",\n      \"method\": \"T cell-specific Kidins220 KO mouse model, Aiolos KO mouse model, scRNA-seq, flow cytometry, apoptosis assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with two KO models and scRNA-seq, single lab\",\n      \"pmids\": [\"38489359\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Aiolos facilitates eosinophil tissue homing by supporting IL-5 production and ST2+ ILC2 proliferation through inhibiting PD-1. Aiolos deficiency reduces eosinophil CCR3 surface expression, intracellular ERK1/2 signaling, and CCL11-induced actin polymerization, impairing chemotaxis.\",\n      \"method\": \"Aiolos-deficient mouse model, chimeric mouse model (intrinsic requirement), flow cytometry, ERK1/2 signaling assays, actin polymerization assay, in vivo inflammatory models\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null plus chimeric model establishing intrinsic requirement, multiple signaling assays, single lab\",\n      \"pmids\": [\"34341502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In vitro acute protein degradation in mice revealed that Aiolos (together with Ikaros) acts as a dedicated transcriptional repressor to cooperatively control early B cell development; both directly repress surrogate light chain genes Igll1 and Vpreb1 in small pre-B cells.\",\n      \"method\": \"Acute protein degradation (auxin-inducible degron) in mice, ChIP-seq, RNA-seq, chromatin accessibility assays\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — acute protein degradation combined with ChIP-seq directly demonstrating repressor function at specific target loci, rigorous method\",\n      \"pmids\": [\"39179932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Aiolos restrains intestinal intraepithelial lymphocyte (IEL) activation; Ikzf3-/- CD8αα+ IELs show elevated NK receptors, cytotoxic enzymes, cytokines, and chemokines. Aiolos binding sites are proximal to STAT5 and RUNX binding sites, and Ikzf3 deficiency increases chromatin accessibility and histone acetylation in these regions. Ikzf3 deficiency enhances IL-15 responsiveness of IELs.\",\n      \"method\": \"Ikzf3-/- mouse model, scRNA-seq, ATAC-seq (chromatin accessibility), histone acetylation assays, IL-15 signaling assays, colitis model\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic null with scRNA-seq, ATAC-seq, and functional signaling assays, multiple orthogonal methods\",\n      \"pmids\": [\"38049581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Aiolos (IKZF3) represses Eos (IKZF4) expression by antagonizing STAT5-dependent activation of the Ikzf4 promoter; this establishes opposing roles of Aiolos and Eos in regulating CD4-CTL cytotoxic programming.\",\n      \"method\": \"Aiolos-deficient and Eos-deficient mouse models (influenza infection), ChIP (STAT5 occupancy at Ikzf4 promoter), flow cytometry, gene expression analysis\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic null models with ChIP demonstrating direct promoter regulation, single lab\",\n      \"pmids\": [\"38363226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"OTUB1, a deubiquitinating enzyme, specifically binds Aiolos and reduces its ubiquitination, potentially influencing Aiolos stability and its biological functions in lung cancer cell migration and invasion.\",\n      \"method\": \"Co-immunoprecipitation (OTUB1-Aiolos interaction), ubiquitination assays, functional cell migration and invasion assays\",\n      \"journal\": \"Heliyon\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single Co-IP with functional overexpression assays, single lab, limited mechanistic detail in abstract\",\n      \"pmids\": [\"39315162\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Intestinal-specific transcription factor AhR binds the Ikzf3 locus, increases chromatin accessibility at an intestinal ILC2-specific open chromatin region, and promotes Ikzf3 transcription by enhancing H3K27ac, establishing AhR as an upstream regulator of Aiolos expression in intestinal ILC2s.\",\n      \"method\": \"ChIP (AhR binding at Ikzf3 locus), ATAC-seq (chromatin accessibility), H3K27ac ChIP-seq, gene expression analysis\",\n      \"journal\": \"Mucosal immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with epigenetic marks demonstrating direct regulation, single lab\",\n      \"pmids\": [\"34349237\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IKZF3 (Aiolos) is a lymphoid zinc finger transcription factor that functions primarily as a transcriptional repressor by recruiting HDAC complexes (via mSin3 and NuRD) to silence target genes including IL-2, c-Myc, surrogate light chain genes, p66Shc, and interferon-stimulated genes; it heterodimerizes with Ikaros to cooperatively regulate lymphocyte development, and its subcellular localization and activity are modulated by IL-2-induced tyrosine phosphorylation and by PBK/TOPK-mediated phosphorylation during mitosis; its protein stability is regulated by the CRBN-CRL4 E3 ubiquitin ligase (which mediates IMiD/CELMoD drug-induced degradation) and by the deubiquitinase OTUB1; disease-associated missense variants in its DNA-binding domain (ZF2-3) cause dominant-negative interference with IKAROS through altered heterodimer DNA binding specificity, while haploinsufficiency variants in ZF5-6 or the stability domain impair lymphocyte development and humoral immunity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IKZF3 (Aiolos) is a lymphoid zinc finger transcription factor that acts predominantly as a sequence-specific transcriptional repressor governing lymphocyte development, differentiation, and activation [#33, #11]. It heterodimerizes with Ikaros, and homo- versus heteromeric complexes carry distinct transcriptional activities, with dominant-negative Ikaros isoforms interfering with Aiolos function [#2]. Repression is executed through two repression domains that recruit mSin3 and the NuRD nucleosome-remodeling/deacetylase machinery to drive promoter histone deacetylation, and is relieved by HDAC inhibitors [#4, #17]. Aiolos directly binds and silences a defined target set including the surrogate light chain genes Igll1/Vpreb1, c-Myc, Il2, and interferon-stimulated genes such as CD38, thereby enforcing cell-cycle withdrawal and developmental checkpoints [#33, #9, #11, #17]. DNA binding requires intact zinc-finger residues (N160) and directs the protein to pericentromeric heterochromatin [#24, #18]. Across lineages it shapes B cell development and high-affinity plasma cell generation, NK cell maturation, TH17, TFH, CD4/CD8 cytotoxic and virtual-memory programming, and tissue lymphocyte restraint, often by co-opting or antagonizing STAT5/STAT1 activity at target loci [#8, #12, #26, #25, #34]. Aiolos protein abundance is controlled by the CRBN-CRL4 E3 ubiquitin ligase, which mediates IMiD/CELMoD drug-induced ubiquitination and proteasomal degradation [#0, #1, #16], and its chromatin association is dynamically regulated by phosphorylation, including PBK/TOPK-mediated eviction during mitosis [#29]. Heterozygous missense variants in the DNA-binding zinc fingers cause disease through dominant-negative heterodimeric interference with IKAROS, altering DNA-binding specificity to drive immunodeficiency and CLL-like malignancy, whereas variants affecting dimerization or the stability domain cause haploinsufficiency [#18, #19, #20, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established Aiolos as an Ikaros-family partner whose transcriptional output depends on the composition of its dimeric complexes, defining the combinatorial logic of the family.\",\n      \"evidence\": \"Molecular cloning with heterodimerization and transcriptional activity assays\",\n      \"pmids\": [\"9155026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define DNA target sequences\", \"Did not identify co-repressor machinery\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined the molecular mechanism of repression by linking Aiolos/Ikaros repression domains to mSin3-HDAC recruitment and promoter histone deacetylation.\",\n      \"evidence\": \"In vivo/in vitro Co-IP, HDAC inhibitor treatment, and histone acetylation assays\",\n      \"pmids\": [\"10357820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not map endogenous target genes\", \"Did not address NuRD versus mSin3 selectivity\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated through genetic ablation that Aiolos negatively regulates BCR signaling and is required for specific peripheral B cell populations, anchoring its physiological role in B lymphocytes.\",\n      \"evidence\": \"Aiolos-null mouse with BCR stimulation, flow cytometry, and immunization\",\n      \"pmids\": [\"9806640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify direct target genes underlying the phenotype\", \"Cell-intrinsic versus extrinsic contribution not resolved here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified direct developmental targets, showing Aiolos enforces the pre-B checkpoint by silencing and repositioning surrogate light chain genes, later confirmed by acute degradation/ChIP-seq.\",\n      \"evidence\": \"Aiolos/OBF-1 double-KO mice, FISH repositioning, and auxin-inducible degron with ChIP-seq\",\n      \"pmids\": [\"18974788\", \"39179932\", \"17971486\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of locus repositioning incompletely defined\", \"Relative contribution of OBF-1 antagonism versus direct repression\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected Aiolos repressor activity to proliferative control by showing direct binding and suppression of the c-Myc promoter precedes cell-cycle exit.\",\n      \"evidence\": \"ChIP and gain/loss-of-function in pre-B cells\",\n      \"pmids\": [\"20566697\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor complex at the c-Myc promoter not specified\", \"Direct versus indirect p27/cyclin D3 effects\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended the repressor model to T helper differentiation by identifying upstream inducers (STAT3/AhR) and a direct Il2 silencing event driving TH17 fate.\",\n      \"evidence\": \"Aiolos-deficient mice with TH17 differentiation and Il2 chromatin analysis\",\n      \"pmids\": [\"22751139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide TH17 target set not fully defined\", \"Co-repressor recruitment in T cells not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed that IMiD drugs act by hijacking the CRBN-CRL4 ligase to ubiquitinate and degrade Aiolos, explaining their anti-tumor and immunomodulatory effects.\",\n      \"evidence\": \"Quantitative proteomics, ubiquitination assays, and mutagenesis-based rescue\",\n      \"pmids\": [\"24292625\", \"24328678\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degron structural basis not yet defined in these studies\", \"Downstream transcriptional consequences of degradation not fully mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided the structural and kinetic basis for differential drug-induced degradation, with crystallography of cereblon-compound complexes and rate-of-degradation correlations to efficacy.\",\n      \"evidence\": \"X-ray crystallography of cereblon-DDB1-CC-220 plus kinetic degradation assays\",\n      \"pmids\": [\"28425720\", \"26430725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full Aiolos degron contacts not resolved in the structure\", \"In vivo kinetics in patients not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed Aiolos loss alone recapitulates IMiD effects in myeloma and that Aiolos/Ikaros repress interferon-stimulated genes (including CD38) via NuRD, linking degradation to an interferon-like death program.\",\n      \"evidence\": \"CRISPR knockout, RNA-seq, NuRD Co-IP, and CD38/ADCC assays\",\n      \"pmids\": [\"30228232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect ISG regulation not fully separated\", \"NuRD subunit selectivity not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the disease mechanism of zinc-finger missense variants as dominant-negative heterodimeric interference that redirects DNA binding, causing immunodeficiency and CLL-like malignancy.\",\n      \"evidence\": \"Knockin and conditional knockin mouse models with ChIP-seq, DNA binding, and dimerization-deficient rescue\",\n      \"pmids\": [\"34155405\", \"33689703\", \"34694366\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why specific neomorphic genomic sites are bound is unresolved\", \"Penetrance determinants of malignancy unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined post-translational and domain-level control of Aiolos: PBK/TOPK phosphorylation evicts it from mitotic chromosomes, and ZF5-6/stability-domain variants cause haploinsufficiency, distinguishing dominant-negative from loss-of-expression mechanisms.\",\n      \"evidence\": \"Pbk-/- mice with chromatin proteomics/ATAC-seq, and patient variant biochemistry/stability assays\",\n      \"pmids\": [\"40987773\", \"38015619\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of mitotic eviction for gene expression not fully traced\", \"OTUB1-mediated stabilization (#36) rests on a single low-confidence Co-IP\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Broadened the lineage role of Aiolos by showing it binds AP-1 factors and balances STAT5/STAT1-driven programs across NK, CD4-CTL, virtual-memory, and tissue lymphocytes, acting as a node that tunes cytokine responsiveness.\",\n      \"evidence\": \"Conditional double KO with ChIP, plus multiple Ikzf3-/- models with ChIP for STAT occupancy\",\n      \"pmids\": [\"38182668\", \"36964178\", \"41392082\", \"38049581\", \"38363226\", \"39560988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT antagonism is via direct competition or chromatin closure varies by locus\", \"Co-repressor requirement in these contexts not uniformly tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the choice between canonical repression complexes (mSin3 vs NuRD), neomorphic DNA targeting by mutants, and lineage-specific STAT partnering is mechanistically selected remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of Aiolos-DNA or Aiolos-co-repressor complexes\", \"Rules governing context-specific target selection unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 4, 11, 33]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [18, 24, 33]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [4, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [21, 24]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [21, 24, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 11, 33]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 8, 12, 26]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 17, 29, 34]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0, 1, 16]}\n    ],\n    \"complexes\": [\"NuRD complex\", \"mSin3-HDAC co-repressor complex\", \"CRL4(CRBN) E3 ubiquitin ligase (substrate)\"],\n    \"partners\": [\"IKZF1\", \"CRBN\", \"PRDM1\", \"PBK\", \"OTUB1\", \"STAT5\", \"STAT1\", \"POU2AF1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}